1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Demographic and clinical data
Pt No. Age (y)/Sex TNM Staging Tumor Response PFS 1 40/M T3N2aM0 PR 6 2 34/M T4N2cM0 PR 14 3 57/M T4N1M0 SD 6 4 59/M T4N2cM0 SD 12 5 45/M T4N3M0 PR 11 6 55/F T4N2bM0 PR 24 7 59/M T4N3M0 SD 4 8 62/M T4N2cM0 SD 24 9 61/M T4N3M0 SD 14 10 47/M T4N2cM0 PR 15 11 72/M T4N3M0 PR 6 12 49/M T4N2cM0 SD 8 13 57/M T4N2cM0 PR 8 14 64/M T4N1M0 PR 4 15 53/M T4N2cM0 SD 11 16 56/M T4N3M0 SD 5 17 62/F T4N2cM0 PR 10 18 65/M T4N3M0 PR 13 19 59/M T4N2cM0 PR 12
Note:—TNM indicates tumors, nodes, and metastasis; PR indicates partial response; SD, stable disease; PFS, progression-free survival (in months).